BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 32313727)

  • 1. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.
    Dancsok AR; Gao D; Lee AF; Steigen SE; Blay JY; Thomas DM; Maki RG; Nielsen TO; Demicco EG
    Oncoimmunology; 2020; 9(1):1747340. PubMed ID: 32313727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells.
    Nyström H; Jönsson M; Nilbert M; Carneiro A
    Acta Oncol; 2023 Jan; 62(1):33-39. PubMed ID: 36786033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer.
    Giatromanolaki A; Mitrakas A; Anestopoulos I; Kontosis A; Koukourakis IM; Pappa A; Panayiotidis MI; Koukourakis MI
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.
    Yang H; Yan M; Li W; Xu L
    J Transl Med; 2022 Mar; 20(1):140. PubMed ID: 35317832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis.
    Chen Y; Klingen TA; Aas H; Wik E; Akslen LA
    J Pathol Clin Res; 2023 May; 9(3):151-164. PubMed ID: 36598153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
    Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
    Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade.
    Ozaniak A; Smetanova J; Bartolini R; Rataj M; Capkova L; Hacek J; Fialova M; Krupickova L; Striz I; Lischke R; Bartunkova J; Strizova Z
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3789-3801. PubMed ID: 35986756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments.
    Benesova I; Capkova L; Ozaniak A; Pacas P; Kopeckova K; Galova D; Lischke R; Buchler T; Ozaniak Strizova Z
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):134. PubMed ID: 38493445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.
    Liu J; Xavy S; Mihardja S; Chen S; Sompalli K; Feng D; Choi T; Agoram B; Majeti R; Weissman IL; Volkmer JP
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy.
    Chen S; Zhan S; Ding S; Zhang Q; Xuan H; Zhang X; Cao L
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16609-16621. PubMed ID: 37715830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.